Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.57 |
| ▸ | KDR | P35968 | 2/20 | 0.57 |
| ▸ | GABRP | O00591 | 12/20 | 0.49 |
| ▸ | GABRD | O14764 | 12/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 12/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 12/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 12/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 12/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 12/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 12/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 12/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 12/20 | 0.49 |
| ▸ | GABRA4 | P48169 | 12/20 | 0.49 |
| ▸ | GABRE | P78334 | 12/20 | 0.49 |
| ▸ | GABRA6 | Q16445 | 12/20 | 0.49 |
| ▸ | GABRG1 | Q8N1C3 | 12/20 | 0.49 |
| ▸ | GABRG3 | Q99928 | 12/20 | 0.49 |
| ▸ | GABRQ | Q9UN88 | 12/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7707193 | 0.91 | GABRP (0.60) | SRCKDRGABRPGABRDGABRA1 | |
| SCHEMBL10482885 | 0.82 | GABRP (0.64) | SRCKDRGABRPGABRDGABRA1 | |
| SCHEMBL7713174 | 0.80 | GABRA2 (0.70) | SRCKDRGABRPGABRDGABRA1 | |
| SCHEMBL6208684 | 0.78 | SRC (0.57) | SRCKDRGABRPGABRDGABRA1 | |
| SCHEMBL10581666 | 0.77 | GABRA2 (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10571672 | 0.76 | GABRB3 (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7965709 | 0.76 | SRC (0.58) | SRCKDRGABRPGABRDGABRA1 | |
| SCHEMBL7707477 | 0.76 | GABRP (0.74) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7967756 | 0.76 | GABRP (0.61) | SRCKDRGABRPGABRDGABRA1 | |
| SCHEMBL6208048 | 0.76 | KDR (0.57) | SRCKDRGABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383769-A4 | 6-SUBSTITUTED PYRAZOLO 3,4-D]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-08-03 | — | — | EP | disclosed |
| EP-1121363-B1 | 6-SUBSTITUTED PYRAZOLO(3,4-d)PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-12-22 | — | — | EP | disclosed |
| EP-1383769-A2 | 6-SUBSTITUTED PYRAZOLO 3,4-D]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2004-01-28 | — | — | EP | disclosed |
| US-6559152-B2 | For therapy of cancer or other proliferative diseases | DUPONT PHARMACEUTICALS COMPANY | 2003-05-06 | — | — | US | disclosed |
| US-6531477-B1 | Treating cancer or other proliferative diseases | DUPONT PHARMACEUTICALS COMPANY | 2003-03-11 | — | — | US | disclosed |
| WO-2002067654-A3 | 6-SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002067654-A2 | 6-SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-09-06 | — | — | WO | disclosed |
| US-20020013328-A1 | 6-Substituted pyrazolo[3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | disclosed |
| EP-1121363-A2 | 6-SUBSTITUTED PYRAZOLO 3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000021926-A2 | 6-SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013328-A1 | 6-Substituted pyrazolo[3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors | CCNK, CCNI, CDK1 | SRC 1160/4885KDR 2834/4885GABRP 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.